Table 2.
Genes or products | Population | Phenotypes | References | |
---|---|---|---|---|
CD8+ | Dominant TCR Clonotypes | Elite; LTNP | Better duration; Cross reactivity | (87–89) |
KK10-specific TCR clonotype BV27-CASSGGRRAF/J1-1 |
Elite vs. Progressors (4% vs. 20%) | Less effective | (87) | |
KK10-specific TCR clonotype BV21-CASTNRGSEQY/J2-7 |
Elite vs. Progressors (4% vs. 17.7%) | Less effective | (87) | |
Preservation of CD73 on cells | Elite | Normal function | (90) | |
Up regulation of PD-1 | LTNPs vs. TP (16.3% vs. 45.2%) | Reduced CD4+ T cells; Increased VLs | (91, 92) | |
Increase of HLA-G+ | Controllers | Higher CD4+ T cells; Lower VLs | (93) | |
CD4+ | Gag293-specific TCR clonotype TRAV24 | Controller vs. treated patients (44% vs. 13%) | Superior functions | (94) |
Gag293-specific TCR clonotype TRBV2 | Controller vs. treated patients (82% vs. 28%) | Superior functions | (94) | |
CD45RA+CCR7− | LTNPs | IFN-γ secreting | (95) | |
Depletion of CD73+ on cells | Progressors | Reduced CD4+ T cells | (96) | |
Frequency of Tregs of CD45RA+CD27−CCR7− CD62L− and CD45RA−CD27−CCR7−CD62L− | ART− population | Higher VLs within total CD4+ T cells | (97) | |
CTLA-4 on Tregs | Infected population | Corresponding to stages of disease | (98) | |
ICOS on Tregs | Infected population | Corresponding to stages of disease | (98) | |
Steady CD39 on Tregs | Elite | Stable CD4+ T cells; | (98) | |
Preserved Vγ2Vδ2 β7Hi |
NVSs Progressors |
Suppressed VLs; Higher CD56 Higher risk of infection; More rapid progression |
(99) (100) |